Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| CD30 Hu 2013 (Blood); classical Hodgkin lymphoma is CD30-positive by definition | 100% | IHC; CD30 is a defining feature of Hodgkin Reed-Sternberg cells | doi.org |
| CD25 (IL-2 receptor alpha) Strauchen and Breakstone 1987 (Am J Pathol), 166-case series; positivity includes Reed-Sternberg cells | 58% | IHC (anti-Tac), IL-2 receptor in >10% of cells, 12 Hodgkin's disease cases | PMC |
| Exportin-1 (XPO1) Small series; the same study found XPO1 mutations in 24% of primary mediastinal B-cell lymphoma (28 of 117) and in under 2% of other diffuse large B-cell lymphoma | 26% | XPO1 mutation (mostly E571K), sequencing, 5 of 19 cases | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.